LAPI LABORATORIES - Indonesia - search results

United States - English - NLM (National Library of Medicine)

varubi- rolapitant tablet varubi- rolapitant injection, emulsion

glaxosmithline llc - rolapitant hydrochloride (unii: 57o5s1qsaq) (rolapitant - unii:nle429izuc) - rolapitant 90 mg - varubi® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. varubi is contraindicated in patients: risk summary the limited data with varubi use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. in animal reproduction studies, there were no adverse developmental effects observed with oral administration of rolapitant in rats and rabbits during the period of organogenesis at doses up to 1.3 times and 2.9-times, respectively, the maximum recommended human dose (mrhd) [see data] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defec

European Union - English - EMA (European Medicines Agency)

varuby

tesaro bio netherlands b.v. - rolapitant - vomiting; nausea; cancer - antiemetics and antinauseants, - prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.varuby is given as part of combination therapy.